The End of Nihilism

Systemic Therapy of Advanced Non-Small Cell Lung Cancer

Vinicius Ernani, Conor E. Steuer, Mohammad Jahanzeb

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer death in the United States and many other parts of the world. Non-small cell lung cancer (NSCLC) comprises 85-90% of lung cancers. Historically, the expected survival of patients with advanced disease has been estimated in months. In recent years, however, lung cancer has come to be seen as a treatable disease with multiple therapeutic options. Enormous advances in the understanding of its pathways and mechanisms have enabled personalized therapy in NSCLC. The evolving approach to therapy focuses on genomic profiling of the tumors to find molecular targets and develop specific agents for individualized therapy. In addition, maintenance therapy has emerged as a valid approach, and the choice of chemotherapy now varies by histology. Most recently, immunotherapy with checkpoint inhibitors has shown promising results, with impressive durations of response and a tolerable toxicity profile. Together, these discoveries have improved overall survival substantially in patient populations that have access to these advancements. We review the clinical data surrounding these impressive improvements.

Original languageEnglish (US)
Pages (from-to)153-168
Number of pages16
JournalAnnual Review of Medicine
Volume68
DOIs
StatePublished - Jan 14 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Cells
Histology
Chemotherapy
Lung Neoplasms
Toxicity
Tumors
Therapeutics
Survival
Immunotherapy
Cause of Death
Neoplasms
Drug Therapy
Population

Keywords

  • Advanced NSCLC
  • chemotherapy
  • immunotherapy
  • maintenance therapy
  • targeted therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The End of Nihilism : Systemic Therapy of Advanced Non-Small Cell Lung Cancer. / Ernani, Vinicius; Steuer, Conor E.; Jahanzeb, Mohammad.

In: Annual Review of Medicine, Vol. 68, 14.01.2017, p. 153-168.

Research output: Contribution to journalReview article

@article{a14393b2d89a4323b547949c25370176,
title = "The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer",
abstract = "Lung cancer is the leading cause of cancer death in the United States and many other parts of the world. Non-small cell lung cancer (NSCLC) comprises 85-90{\%} of lung cancers. Historically, the expected survival of patients with advanced disease has been estimated in months. In recent years, however, lung cancer has come to be seen as a treatable disease with multiple therapeutic options. Enormous advances in the understanding of its pathways and mechanisms have enabled personalized therapy in NSCLC. The evolving approach to therapy focuses on genomic profiling of the tumors to find molecular targets and develop specific agents for individualized therapy. In addition, maintenance therapy has emerged as a valid approach, and the choice of chemotherapy now varies by histology. Most recently, immunotherapy with checkpoint inhibitors has shown promising results, with impressive durations of response and a tolerable toxicity profile. Together, these discoveries have improved overall survival substantially in patient populations that have access to these advancements. We review the clinical data surrounding these impressive improvements.",
keywords = "Advanced NSCLC, chemotherapy, immunotherapy, maintenance therapy, targeted therapy",
author = "Vinicius Ernani and Steuer, {Conor E.} and Mohammad Jahanzeb",
year = "2017",
month = "1",
day = "14",
doi = "10.1146/annurev-med-042915-102442",
language = "English (US)",
volume = "68",
pages = "153--168",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - The End of Nihilism

T2 - Systemic Therapy of Advanced Non-Small Cell Lung Cancer

AU - Ernani, Vinicius

AU - Steuer, Conor E.

AU - Jahanzeb, Mohammad

PY - 2017/1/14

Y1 - 2017/1/14

N2 - Lung cancer is the leading cause of cancer death in the United States and many other parts of the world. Non-small cell lung cancer (NSCLC) comprises 85-90% of lung cancers. Historically, the expected survival of patients with advanced disease has been estimated in months. In recent years, however, lung cancer has come to be seen as a treatable disease with multiple therapeutic options. Enormous advances in the understanding of its pathways and mechanisms have enabled personalized therapy in NSCLC. The evolving approach to therapy focuses on genomic profiling of the tumors to find molecular targets and develop specific agents for individualized therapy. In addition, maintenance therapy has emerged as a valid approach, and the choice of chemotherapy now varies by histology. Most recently, immunotherapy with checkpoint inhibitors has shown promising results, with impressive durations of response and a tolerable toxicity profile. Together, these discoveries have improved overall survival substantially in patient populations that have access to these advancements. We review the clinical data surrounding these impressive improvements.

AB - Lung cancer is the leading cause of cancer death in the United States and many other parts of the world. Non-small cell lung cancer (NSCLC) comprises 85-90% of lung cancers. Historically, the expected survival of patients with advanced disease has been estimated in months. In recent years, however, lung cancer has come to be seen as a treatable disease with multiple therapeutic options. Enormous advances in the understanding of its pathways and mechanisms have enabled personalized therapy in NSCLC. The evolving approach to therapy focuses on genomic profiling of the tumors to find molecular targets and develop specific agents for individualized therapy. In addition, maintenance therapy has emerged as a valid approach, and the choice of chemotherapy now varies by histology. Most recently, immunotherapy with checkpoint inhibitors has shown promising results, with impressive durations of response and a tolerable toxicity profile. Together, these discoveries have improved overall survival substantially in patient populations that have access to these advancements. We review the clinical data surrounding these impressive improvements.

KW - Advanced NSCLC

KW - chemotherapy

KW - immunotherapy

KW - maintenance therapy

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85009977105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009977105&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-042915-102442

DO - 10.1146/annurev-med-042915-102442

M3 - Review article

VL - 68

SP - 153

EP - 168

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -